Stay updated with breaking news from Aulos Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Biolojic Design, a unique technology company pioneering computational design of human antibodies to develop smart therapeutic solutions for...
Press release content from Business Wire. The AP news staff was not involved in its creation.
Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer News provided by Share this article Share this article LARKSPUR, Calif., May 17, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today that Leo Redmond will join the company as chief financial officer. Redmond brings to Aulos nearly three decades of financial experience in the biopharmaceutical industry. He will be based in the company's new headquarters in Larkspur, California. "We a...
Aulos Bioscience Appoints Aron Knickerbocker as CEO News provided by Share this article Share this article BOSTON and TEL AVIV, Israel, March 15, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today that Aron Knickerbocker has joined the company as its chief executive officer and a member of its board of directors, effective immediately. Yanay Ofran, Ph.D., CEO of Biolojic Design and co-founder and founding CEO of Aulos, will continue to s...
Hits: 772 Aulos Bioscience to Present at the 39th Annual J.P. Morgan Healthcare Conference BOSTON, MA, USA and TEL AVIV, Israel I January 8, 2021 I ATP, a leading life sciences venture capital firm, and Biolojic Design, a biotechnology company that computationally designs functional antibodies, today unveiled Aulos Bioscience, a new company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors. ATP has committed $40 million in Series A funding to advance Aulos' lead molecule from preclinical stage through clinica...